Lykos' longtime CEO to step down in latest shakeup after MDMA drug setback
Adds background throughout
Sept 5 (Reuters) -Lykos Therapeutics said on Thursday longtime CEO Amy Emerson would step down from the role, in the latest shakeup after the U.S. health regulator declined to approve its MDMA-based treatment for post-traumatic stress disorder.
Michael Mullette, chief operating officer since early 2022 after over two decades with Sanofi SASY.PA and Moderna MRNA.O, will be the interim CEO, the company said.
Lykos, formerly known as MAPS Public Benefit Corp, laid off 75% of its workforce and said founder Rick Doblin would leave the board, days after the U.S. Food and Drug Administration's decision.
The health regulator in August declined to approve the company's treatment and asked for an additional late-stage trial.
Emerson, who has led Lykos since its founding in 2014, will transition into a senior adviser role.
Reporting by Christy Santhosh; Editing by Shilpi Majumdar and Sriraj Kalluvila
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.